WO2011118468A1 - Agent de prolongation de l'heure de réveil - Google Patents

Agent de prolongation de l'heure de réveil Download PDF

Info

Publication number
WO2011118468A1
WO2011118468A1 PCT/JP2011/056192 JP2011056192W WO2011118468A1 WO 2011118468 A1 WO2011118468 A1 WO 2011118468A1 JP 2011056192 W JP2011056192 W JP 2011056192W WO 2011118468 A1 WO2011118468 A1 WO 2011118468A1
Authority
WO
WIPO (PCT)
Prior art keywords
time
terrestrial
awakening time
lutein
microorganism
Prior art date
Application number
PCT/JP2011/056192
Other languages
English (en)
Japanese (ja)
Inventor
内田　勝幸
成臣 山田
伊藤　裕之
Original Assignee
株式会社明治
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社明治 filed Critical 株式会社明治
Priority to IN6612DEN2012 priority Critical patent/IN2012DN06612A/en
Priority to CN2011800152193A priority patent/CN102933210A/zh
Priority to JP2012506960A priority patent/JPWO2011118468A1/ja
Publication of WO2011118468A1 publication Critical patent/WO2011118468A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a wakefulness-prolonging agent comprising a land animal, a land plant or a microorganism-derived carotene oxidant as an active ingredient.
  • Carotenoid is a general term for the hydrocarbons carotenes in which eight isoprenoid units are bonded.
  • Carotenoids are natural pigments that are distributed in plants, microorganisms and animals, have a physiological effect as provitamin A, such as ⁇ -carotene, and the active ingredients of herbal medicines such as crocin and crocetin, and the coloring of foods containing these Some important fees are included.
  • provitamin A such as ⁇ -carotene
  • crocin and crocetin the active ingredients of herbal medicines
  • crocin and crocetin auxiliary enzyme in light energy transmission
  • fucoxanthin which is one of the fat-soluble substances contained in seaweeds such as hijiki and seaweed, has anti-obesity action (Non-patent Document 2), neutral fat absorption inhibitory action (Patent Document 1), and the like.
  • astaxanthin which is contained in crustaceans such as shrimp and crab and used as a red pigment, has an in vivo antioxidant action (Patent Document 3) and has an effect of improving liver function (patent) Document 4) has been found. Furthermore, astaxanthin has also been found to have an effect of improving muscle damage and disease (Patent Document 2).
  • lutein a type of carotenoid
  • lutein is a pigment present in plant leaves, flowers, fruits and egg yolks.
  • Lutein has long been used as a food additive for coloring, but it has recently been used as a functional food material because it has effects such as eyestrain based on antioxidant action and suppression of cataract and age-related macular degeneration. Also attracting attention.
  • Patent Document 5 discloses a composition for eye strain containing lutein.
  • Patent Document 6 discloses a nutritional supplement for treating macular degeneration containing lutein.
  • Patent Document 7 discloses a circadian rhythm normalizing composition containing astaxanthin which is a kind of carotenoid and / or its ester as an active ingredient.
  • the invention described in Patent Document 7 has an action in which astaxanthin effectively regulates the daily rhythm by increasing the utilization rate of melatonin in vivo, and is a rat sleep time zone in a rat experiment. This is based on the action of reducing the activity ratio of the light period with astaxanthin. That is, the circadian rhythm normalization composition described in Patent Document 7 affects sleep.
  • circadian rhythm normalizing composition described in Patent Document 7 affects sleep time, there remains a question as to whether it is possible to improve the poor sleep due to the small amount of exercise during the activity time.
  • astaxanthin which is a circadian rhythm normalizing composition described in Patent Document 7, belongs to marine carotenoids. For example, when applied to food and drink such as dairy products, the odor derived from raw materials becomes a problem, and there is a problem in terms of flavor. It will remain.
  • the present invention has been made in view of the above situation, and the problem to be solved by the present invention is that it is safe and easy to obtain, and does not cause a problem of flavor even when combined with other foods and ingredients. It is to provide a time extender, and at the same time, to provide a food / beverage product, a food composition, and a pharmaceutical composition using the awakening time extender.
  • the present inventors conducted extensive research and found that the action of extending the awakening time to carotenylated derivatives derived from terrestrial animals, terrestrial plants or microorganisms was found.
  • an awakening time prolonging agent comprising a caroten-oxidized derivative derived from a land animal, a land plant or a microorganism as an active ingredient.
  • an awakening time extending agent comprising a caroten-oxidized derivative derived from a land animal, a land plant or a microorganism as an active ingredient.
  • the above terrestrial animal, terrestrial plant or microorganism-derived carotene oxidation derivative is lutein, zeaxanthin, crocin, spheroidene, violaxanthin, torularhodinaldehyde ), Torularhodin, capsanthin, crocetin, bixin, azafrin, ⁇ -carotenone, beta-carotenone, eschscholtzxanthin, rhodoxanthin, cap
  • a method for extending awakening time comprising a step of administering to a subject a pharmaceutically effective amount of a carotenylated derivative derived from a land animal, a land plant or a microorganism.
  • a pharmaceutically effective amount of a carotenylated derivative derived from a land animal, a land plant or a microorganism comprising at least one of a hydroxyl group, a carbonyl group, and an ether group.
  • the above-mentioned terrestrial animal, terrestrial plant or microorganism-derived carotene oxidation derivative is selected from the group consisting of lutein, zeaxanthin, crocin, spheroidene, violaxanthin, torularhodinaldehyde ), Torularhodin, capsanthin, crocetin, bixin, azafrin, ⁇ -carotenone, beta-carotenone, eschscholtzxanthin, rhodoxanthin, cap [7] or [8], wherein at least one of (decaprenoxanthin) is an active ingredient.
  • the carotenylated derivatives derived from terrestrial animals, terrestrial plants or microorganisms are lutein, zeaxanthin, crocin, spheroidene, violaxanthin, torularhodinaldehyde ), Torularhodin, capsanthin, crocetin, bixin, azafrin, ⁇ -carotenone, beta-carotenone, eschscholtzxanthin, rhodoxanthin, cap
  • the awakening time extender of the present invention is useful as a food or drink or a medicine for shortening the sleeping time and prolonging the awakening time.
  • the food / beverage / beverage-drink material or the drug / drug material having an arousal action in which the agent for extending the arousal time of the present invention is blended comprises a land animal, a land plant or a microorganism-derived carotene oxidation derivative as an active ingredient. It is safe because it has abundant dietary experience and few side effects. Furthermore, the odor derived from the raw material is much less than the conventional odor and is excellent in flavor. Also, by ingesting, taking, or administering the wakefulness extending agent of the present invention, for example, by spending longer wakefulness during the day and becoming active, it is possible to have good quality sleep during the sleeping hours. Obtainable.
  • the carotenylated derivatives derived from land animals, land plants or microorganisms in the present invention are not particularly limited as long as they are carotenylated derivatives derived from, for example, vegetables, fruits and microorganisms containing carotenoids.
  • the carotene oxidized derivative of the present invention can contain at least one of a hydroxyl group, a carbonyl group, and an ether group.
  • lutein is given and described below.
  • Lutein is abundant in vegetables, fruits and plants. In particular, it is one of carotenoids widely present in the plant world, such as green-yellow vegetables such as kale, brussels sprouts, spinach, broccoli, and yellow flowers such as marigold. Among them, the petals of the Asteraceae are contained in high concentrations in petals and have been used since ancient times as feed for enhancing the coloration of egg yolks in poultry, and in recent years as food colorings that take advantage of their clear yellow color. in use. Lutein is also known to improve eye diseases such as age-related macular degeneration and cataracts. Lutein has a CAS No.
  • Lutein belongs to the alcohol derivative of carotene, and lutein 20S (containing 20% by mass of lutein, Kyowa Hakko Bio Co., Ltd.) is commercially available. Lutein 20S is a reddish brown heat-softening paste containing 20% lutein derived from marigold petals.
  • Extraction of lutein is carried out by impregnating the above-mentioned plants and microorganisms with a solvent at room temperature or in a heated state, or by using a distillation device such as steam distillation in addition to solvent extraction performed using an extraction device such as a Soxhlet extractor.
  • Extraction method, supercritical extraction method using carbon dioxide gas in a supercritical state, or pressing method to obtain an extract by pressing, freeze-dried, and distilled water is added to remove the residue to obtain a supernatant
  • a method or the like can be used.
  • fruit juice or the like can be used after being subjected to treatment such as spray drying.
  • a polar solvent or a nonpolar solvent can be used, and these can also be mixed and used.
  • water alcohols such as methanol, ethanol, propanol and butanol; polyhydric alcohols such as ethylene glycol, propylene glycol and butylene glycol; ketones such as acetone and methyl ethyl ketone; esters such as methyl acetate and ethyl acetate; tetrahydrofuran Linear and cyclic ethers such as diethyl ether; polyethers such as polyethylene glycol; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; hydrocarbons such as hexane, cyclohexane and petroleum ether; benzene and toluene Aromatic hydrocarbons such as; pyridines; supercritical carbon dioxide; oils, waxes, other oils, and the like
  • examples of the means for separating and purifying the extract include activated carbon treatment, liquid-liquid distribution, column chromatography, liquid chromatography, gel filtration, and precision distillation.
  • carotene oxidation derivatives of the present invention include carotene alcohol derivatives (zeaxanthin etc.), glycosides (crocin etc.), ether derivatives (spheroidene etc.), epoxide derivatives (violaxanthin etc.), aldehyde derivatives ( Tolralozinaldehyde, etc.) and carboxylic acid derivatives (tolralodine, etc.), as well as apocarotenoids (crocetin, bixin, azafrine, etc.), secocarotenoids ( ⁇ -carotenone, etc.), retro carotenoids (such as eschertxanthin, rhodoxanthin, etc.), higher carotenoids ( Carotenylated derivatives belonging to decaprenoxanthin and the like, and those derived from land animals, land plants or microorganisms.
  • carotene alcohol derivatives zeaxanthin etc.
  • glycosides crocin etc.
  • Zeaxanthin also called (3R, 3'R) - ⁇ , ⁇ -carotene-3,3'-diol, CAS No. 144-68-3, distributed in corn seeds, physalis, etc., Fluka, EXTRASYNTHESE SA Etc.
  • Crocin (8,8'-Diapo- ⁇ , ⁇ -carotene-8,8'-dioic acid bis (6-O- ⁇ -D-glucopyranosyl- ⁇ -D-glucopyranosyl) ester, CAS No, 42553 -65-1, distributed in saffron stigma, gardenia fruit, etc., available at Sigma / EXTRASYNTHESE SA etc.
  • Spheroidene also known as spheroidene, 3,4-Didehydro-1,2,7 ', 8'-tetrahydro-1-methoxy- ⁇ , ⁇ -carotene, CAS No.
  • Violaxanthin also called violaxanthin, 5 ⁇ , 6 ⁇ : 5' ⁇ , 6' ⁇ -Bisoxy-5,5 ', 6,6'-tetrahydro- ⁇ , ⁇ -carotene-3 ⁇ , 3 ⁇ '-diol, CAS No.
  • Torralodin aldehyde also called torularhodinaldehyde, distributed in Rhodotorula genus yeast
  • Torralodin also called torularhodin, 3 ', 4'-Didehydro- ⁇ , ⁇ -caroten-16'-oic acid, CAS No.
  • Crocetin also referred to as crocetin, 8,8'-Diapo- ⁇ , ⁇ -carotene-8,8'-dioic acid, CAS No, 27876-94-4, saffron stigma, etc., available at EXTRASYNTHESE SA, etc.
  • Bixin also referred to as (9Z) -6,6'-Diapo- ⁇ , ⁇ -carotene-6,6'-dioic acid 6-methyl ester, CAS No.
  • ⁇ -Carotenone also known as ⁇ -carotenone, 5,6,5 ', 6'-Diseco- ⁇ , ⁇ -caroten-5,6,5', 6'-tetrone, distributed in Murraya exotica, etc., CaroteNature Etc.
  • Rhodoxanthin also known as rhodoxanthin, 4 ', 5'-Didehydro-4,5'-retro- ⁇ , ⁇ -carotene-3,3'-dione, CAS No. 116-30-3, yew fruit
  • Decaprenoxanthin decaprenoxanthin, (2R, 2'R, 6R, 6'R) -2,2'-Bis [(E) -4-hydroxy-3-methyl-2-butenyl] - ⁇ , ⁇ -carotene CAS No. 28368-06-1
  • Flavobacterium dehydrogenans bacteria
  • Arthrobacter glacialis bacteria
  • the terrestrial animal, terrestrial plant or microorganism-derived carotene oxidation derivative used in the wakefulness prolonging agent of the present invention is the extract obtained by the method exemplified above or the separated fraction as it is, or appropriately diluted with a solvent. It can be used as a diluting solution, or can be made into a concentrated extract or dry powder, or can be prepared as a paste.
  • the awakening time extending agent of the present invention has an action of extending the awakening time.
  • the awakening time extending agent of the present invention has an action of shortening the sleeping time.
  • the terrestrial animal, terrestrial plant or microorganism-derived carotene oxidation derivative of the present invention has an action of shortening the sleep time and prolonging the awakening time, as shown in Examples below. Therefore, the terrestrial animal, land plant or microorganism-derived carotene-oxidized derivative of the present invention can be used not only as a wakefulness extending agent but also as a sleeping time shortening agent. Furthermore, in order to produce a drug (or a pharmaceutical composition, the same shall apply hereinafter) and a food or drink effective for extending the awakening time, the wakefulness extending agent of the present invention is combined with other additives or food and drink materials. Can be used.
  • the pharmaceuticals and foods and drinks of the present invention include “pharmaceutical compositions or foods and beverages that extend awakening time”, “pharmaceutical compositions or foods and beverages that are used to extend awakening time”, and “pharmaceutical compositions that shorten sleep time” It can also be referred to as “food or drink” or “pharmaceutical composition or food or drink used to shorten sleep time”.
  • the awakening time extender of the present invention is an additive for human or veterinary drugs, quasi-drugs, foods, functional foods, foods for the sick, and foods for specified health use that exert the action of extending the awakening time. It can be used.
  • the present invention can be applied as a human or veterinary drug, a quasi drug, a food, a functional food, a food for a sick person, or a food for specified health, which indicates that the awakening time is extended.
  • those who perform driving operations those who assist driving operations, medical workers, construction workers, etc., who are not allowed to sleep while working and may threaten the life of the person or others, normal time for sleeping It can be used to deal with all people including athletes as well as those who work (eg at night), lack of exercise, middle-aged, and bed rest.
  • the wakefulness extending agent of the present invention makes it possible to obtain a good quality sleep during the sleeping hours by spending more wakefulness during the day and becoming more active.
  • the awakening time can be longer, it is possible to prevent bedridden elderly people and long-term caregivers, and to extend the awakening state of those who are required to be in an awakening state. Can be arranged freely.
  • the wakefulness extending agent when used for treatment or prevention, it is desirable to administer the wakefulness extending agent of the present invention to the subject.
  • the subject of administration of the awakening time prolonging agent of the present invention may be a person who performs driving operation, a person who assists driving operation, a medical worker, or a construction worker, etc. Examples include, but are not limited to, those who are not allowed, those who work normally during sleep (such as at night), those who are under exercise, those who are middle-aged and elderly, and those who are bed rests. It is not a thing.
  • Examples of the dosage form when the awakening time extender of the present invention is used as a pharmaceutical product or quasi-drug include oral administration by tablet, capsule, granule, powder, syrup or the like, injection, suppository, inhalant, Examples include parenteral administration using transdermal absorption agents, external preparations and the like.
  • the carotene-oxidized derivative of the present invention for example, lutein
  • the preferred form is oral administration.
  • it can be produced by a conventional method with the addition of a flavoring agent, a buffering agent, a stabilizer and the like. .
  • Foods and drinks effective for extending the awakening time of the present invention are not limited to categories and types, and may be functional foods and drinks, specified health foods and drinks, health foods and drinks, nursing foods and drinks, confectionery, lactic acid bacteria beverages, It may be a dairy product such as cheese or yogurt, a seasoning or the like.
  • a dairy product such as cheese or yogurt, a seasoning or the like.
  • the above-mentioned food and drink can be produced by ordinary methods of those skilled in the art, but carbohydrates, proteins, lipids can be used as long as they do not hinder the awakening time-extending action of the land animal, land plant or microorganism-derived carotene-oxidized derivative of the present invention. Dietary fiber, vitamins, biologically essential trace metals (manganese sulfate, zinc sulfate, magnesium chloride, potassium carbonate, etc.), fragrances and other compounds can also be added.
  • blend the awakening time extension agent of this invention specifically, various food / beverage products, food-drinks composition (For example, milk, milk drink, soft drink, fermented milk, yogurt, cheese, bread, Biscuits, crackers, pizza crusts, formula milk, liquid foods, foods for the sick, foods such as infant milk powder, foods such as infant milk powder, nutritional foods, etc.) It can be produced by adding an awakening time extending agent comprising a carotene oxide derivative as an active ingredient. Moreover, you may ingest the food / beverage products with which these awakening time extension agents were mix
  • the blending amount of the awakening time extender of the present invention for these foods and drinks or food / beverage product compositions varies depending on the form of use, but the case where the awakening time extender of the present invention is lutein is as follows. is there. In the form of food, it is usually 0.0001 to 10% by mass, more preferably 0.001 to 5% by mass, and particularly preferably 0.002 to 2% by mass. In the case of beverages, it is preferably 0.001 to 0.5% by mass, more preferably 0.005 to 0.25% by mass, and particularly preferably 0.01 to 0.1% by mass.
  • lutein is contained in an amount of 0.1 to 95% by mass, further 1 to 90% by mass, particularly 5 to 50% by mass.
  • the state of the food / beverage products normally used for example, any of solid (powder, granule, etc.), paste, liquid, suspension or gel may be used.
  • lutein is usually 0.01 to 95% by mass, Further, it is preferably 5 to 90% by mass, particularly 10 to 50% by mass.
  • ingredients are also not particularly limited, but when using the wakefulness extender comprising the terrestrial animal, land plant or microorganism-derived carotene oxidation derivative of the present invention as an active ingredient as a food or drink or food composition, water, protein Sugars, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors and the like can be used as main components.
  • the protein examples include whole milk powder, skim milk powder, partially skim milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -casein, ⁇ -lactoglobulin , ⁇ -lactalbumin, lactoferrin, soy protein, chicken egg protein, meat protein, etc., and their hydrolysates; butter, whey minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipid, lactose, etc. And various milk-derived components.
  • saccharide examples include general saccharides, modified starch (in addition to dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like.
  • lipid examples include animal oils such as lard, fish oil, etc., fractionated oils, hydrogenated oil, transesterified oil, etc .; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples include vegetable oils such as hydrogenated oils and transesterified oils.
  • vitamins include vitamin A, carotenes, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline.
  • minerals include, for example, calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium, and whey minerals.
  • organic acid include malic acid, citric acid, lactic acid, and tartaric acid. These components can be used alone or in combination of two or more, and synthetic products and / or foods containing a large amount thereof may be used.
  • the effective intake (dose) of the awakening prolonging agent of the present invention is preferably 0.1 to 1500 mg / 60 kg body weight per day, more preferably 1 to 1200 mg / 60 kg body weight, and particularly preferably 5 to 1000 mg / 60 kg body weight.
  • the electroencephalogram of the rat was measured by a telemetry system for 16 hours from 17:00 to 2 9:00 including 2 hours before and after the dark period (19:00 to 7:00 on the next day), which is the activity time zone of the rat.
  • the obtained electroencephalogram data was analyzed with dedicated analysis software (Somnologica Science, Medcare) to examine changes in arousal, Non-REM sleep, and REM sleep within the measurement time (Biological & Pharmaceutical Bulletin Vol.30 No .10, 2007 p.1895-1897).
  • rats that were in the control group were administered lutein in the same manner as above as the lutein administration group, and those that were in the lutein administration group were given olive oil as the control group. The same measurement as described above was performed.
  • Non-REM sleep time, and REM sleep time in the dark period for each rat are shown in FIG. 1, FIG. 2, and FIG. 3, respectively.
  • the awakening time as shown in FIG. 1, compared to the target olive oil administration, the lutein administration extended the awakening time in most individuals, while the average awakening time in olive oil administration was 368 minutes, Lutein administration showed a tendency to extend the awakening time to 387 minutes.
  • non-REM sleep time as shown in Fig. 2
  • non-REM sleep time was reduced in most individuals by oral administration of lutein as compared to olive oil administration as a control. While sleep time was 249 minutes, non-REM sleep time tended to be shortened to 229 minutes with lutein administration.
  • the average non-REM sleep time in the olive oil administration group was 101 minutes, whereas the lutein administration group was 102 minutes, and no difference was observed.
  • each measurement item value at the time of olive oil administration was calculated from the value of each measurement item at the time of lutein administration shown in FIGS. 1 to 3, and the average of the individual values is shown in FIG. .
  • the administration of lutein showed a tendency to increase the arousal time by about 20 minutes compared with olive oil administration (p ⁇ 0.10), and conversely, non-REM sleep time compared to olive oil administration.
  • the wakefulness-prolonging agent comprising the terrestrial animal, terrestrial plant or microorganism-derived carotene oxidation derivative of the present invention as an active ingredient can prolong the wakefulness time.
  • the awakening time extender of the present invention can be provided in various forms, and since it has less odor derived from raw materials, it can be easily used and provided as a food or drink or a drug that extends the awakening time. can do.
  • the present invention since the present invention has no problem with respect to safety to the human body, the excellent effect can be easily and effectively utilized, and its utility value is high.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un aliment, une boisson ou un matériau médicinal qui est sûr et aisément disponible, ne subit pas la détérioration d'arôme lorsqu'il est combiné avec un autre matériau alimentaire ou matériau, est applicable de manière appropriée à des aliments, des boissons et des agents médicinaux, et a une activité de prolongation de l'heure de réveil. Il est observé qu'un dérivé de carotène oxydé dérivé d'un animal terrestre, une plante terrestre ou un micro-organisme a une activité de raccourcissement du temps de sommeil et de prolongation de l'heure de réveil.
PCT/JP2011/056192 2010-03-24 2011-03-16 Agent de prolongation de l'heure de réveil WO2011118468A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IN6612DEN2012 IN2012DN06612A (fr) 2010-03-24 2011-03-16
CN2011800152193A CN102933210A (zh) 2010-03-24 2011-03-16 觉醒时间延长剂
JP2012506960A JPWO2011118468A1 (ja) 2010-03-24 2011-03-16 覚醒時間延長剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010067524 2010-03-24
JP2010-067524 2010-03-24

Publications (1)

Publication Number Publication Date
WO2011118468A1 true WO2011118468A1 (fr) 2011-09-29

Family

ID=44673025

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/056192 WO2011118468A1 (fr) 2010-03-24 2011-03-16 Agent de prolongation de l'heure de réveil

Country Status (4)

Country Link
JP (2) JPWO2011118468A1 (fr)
CN (1) CN102933210A (fr)
IN (1) IN2012DN06612A (fr)
WO (1) WO2011118468A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108801723B (zh) 2017-05-03 2022-09-13 徕卡显微系统(上海)有限公司 夹紧装置和具有其的切片机

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002223787A (ja) * 2001-02-01 2002-08-13 Yakult Honsha Co Ltd ルテインおよび高純度ルテインの取得方法
JP2008273939A (ja) * 2007-03-30 2008-11-13 Riken Vitamin Co Ltd 睡眠改善剤
JP2009159929A (ja) * 2007-12-13 2009-07-23 Fujifilm Corp 油性組成物
WO2010061574A1 (fr) * 2008-11-25 2010-06-03 財団法人大阪バイオサイエンス研究所 Agent d’amélioration du sommeil, agent sédatif, et utilisation de ceux-ci

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143543A1 (en) * 2007-09-19 2010-06-10 Hans Hitz Nutritional supplement formulations for inclusion in foods and fortified foods comprising such supplements
JP2009242309A (ja) * 2008-03-31 2009-10-22 Ezaki Glico Co Ltd 皮膚外用剤、口腔用組成物および飲食品

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002223787A (ja) * 2001-02-01 2002-08-13 Yakult Honsha Co Ltd ルテインおよび高純度ルテインの取得方法
JP2008273939A (ja) * 2007-03-30 2008-11-13 Riken Vitamin Co Ltd 睡眠改善剤
JP2009159929A (ja) * 2007-12-13 2009-07-23 Fujifilm Corp 油性組成物
WO2010061574A1 (fr) * 2008-11-25 2010-06-03 財団法人大阪バイオサイエンス研究所 Agent d’amélioration du sommeil, agent sédatif, et utilisation de ceux-ci

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOSSEINZADEH, H. ET AL.: "Anxiolytic and hypnotic effect of Crocus sativus aqueous extract and its constituents, crocin and safranal, in mic", PHYTOTHERAPY RESEARCH, vol. 23, no. 6, 2009, pages 768 - 774 *

Also Published As

Publication number Publication date
CN102933210A (zh) 2013-02-13
JP2016028097A (ja) 2016-02-25
JP6049108B2 (ja) 2016-12-21
JPWO2011118468A1 (ja) 2013-07-04
IN2012DN06612A (fr) 2015-10-23

Similar Documents

Publication Publication Date Title
AU725308B2 (en) Anti-stress composition
JPH10155459A (ja) アスタキサンチン含有飲食物
Arumugam et al. Fruits and vegetables as Superfoods: Scope and demand
JP2001200250A (ja) 抗酸化剤
KR101320738B1 (ko) 미세조류 유래 색소를 추출하는 방법 및 추출된 푸코크산틴을 포함하는 비만 또는 당뇨의 예방 또는 치료용 조성물
JP2008297222A (ja) 眼の調節機能障害改善組成物
JPWO2009048120A1 (ja) アスタキサンチン含有水溶性組成物
US20190275096A1 (en) Food-based lutein and zeaxanthin from Momordica Cochinchinensis Spreng, method and composition
JP6049108B2 (ja) 覚醒時間延長剤
JP2015017067A (ja) 育毛促進或いは脱毛を予防及び改善するための、食品、化粧品、医薬品、動物用飼料
JP2012072132A (ja) 寿命延長剤
JP5893438B2 (ja) 網膜症の予防又は改善剤
TW201900159A (zh) 腦功能改善用組成物、乙酸及／或乙酸鹽及其用途
JP2009269832A (ja) カルシトニン遺伝子関連ペプチド及びインスリン様成長因子−１の産生促進組成物
JP6039051B2 (ja) 筋拘縮予防剤
WO2020059745A1 (fr) Composition pour supprimer ou traiter une tumeur cérébrale ou des symptômes attribuables à celle-ci
JP6912214B2 (ja) 赤血球機能向上剤
JPH11266832A (ja) 食用組成物およびその製造法
JP2007051103A (ja) 抗酸化組成物
JP2007099671A (ja) 抗酸化組成物
JP6978103B2 (ja) 網膜保護組成物
WO2020095881A1 (fr) Composition pour augmenter la rétention de carotenoïde dans le sang
Mittu et al. Summary of Natural Products in the Nutraceutical Industry
KR20220162654A (ko) 노각나무 추출물을 유효성분으로 포함하는 시력 보호용 또는 망막 질환의 개선 및 예방용 조성물
JP2012067050A (ja) 高吸収性経口組成物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180015219.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11759274

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012506960

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 6612/DELNP/2012

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11759274

Country of ref document: EP

Kind code of ref document: A1